Bupivacaine/Meloxicam Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Bupivacaine/Meloxicam Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Bupivacaine/Meloxicam can convert its Small molecule drug profile and COX-1 x COX-2 x SCNA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Bupivacaine/Meloxicam (query alias: Bupivacaine/Meloxicam) |
|---|---|
| Modality / target | Small molecule drug; COX-1 x COX-2 x SCNA; COX-1 inhibitors, COX-2 inhibitors, SCNA modulators |
| Highest global status | Approved |
| Originator | Heron Therapeutics, Inc. |
| Active developers | Heron Therapeutics, Inc. |
The MCP disease footprint includes Pain, Postoperative. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600128512 | Not Applicable | Recruiting | 100 | Effective or ineffective subarachnoid block |
| NCT07721571 | Not Applicable | Recruiting | 60 | Postoperative Pain Intensity Assessed Using the Visual Analog Scale |
| ChiCTR2600128406 | Not Applicable | Not yet recruiting | 60 | Postoperative 0–72 h Numerical Rating Scale (NRS) pain intensity score. |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Lidocaine Versus Bupivacaine in Orthognathic Surgery: A Randomized Controlled Trial
Phase 4; n=64; evaluation: not stated. Reported fields: -; 2-Hours Post-Op(Mean) = 3.88 Scores on a scale (Standard Deviation, 2.29); -
Multimodal Management for Perioperative Analgesia in Otolaryngology - Head and Neck Free Flap Reconstructive Surgery: A Prospective Study
Phase 4; n=30; evaluation: not stated. Reported fields: Mean Morphine Equivalents During Stay(Mean) = 222.8 Morphine Milligram Equivalents (MME) (Standard Deviation, 121.4); Mean Morphine Equivalents During Stay(Mean) = 101.9 Morphine Milligram Equivalents (MME) (Standard Deviation, 100.0); -
Treatment of Headache With Occipital Nerve Blocks: Comparison Trial of Anesthetic With or Without Dexamethasone
Phase 4; n=120; evaluation: not stated. Reported fields: -; -; Change in Headache Days 1 Week Following Treatment(Mean) = -1.8 days (Standard Deviation, 2.2)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Bupivacaine/Meloxicam addresses Pain, Postoperative. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-05-13 | Innocoll Pharmaceuticals Limited transferred all data and know-how related to POSIMIR to Durect upon termination of the licensing agreement | Approved | Financial terms not disclosed |
| 2023-12-18 | Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultra-Sustained Pain Therapeutics in Japan | Phase 2 | Financial terms not disclosed |
| 2020-10-29 | Mallinckrodt aims to develop and introduce INL-001, Innocoll's solution for post-operative pain. | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 24 July 2026. Counts and status fields may change as source records update.
